British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

ZURICH :Temenos, a Swiss banking software firm, on Tuesday trimmed its mid-term targets and presented a new plan to boost growth over the next four years by boosting its sales force and focusing on the U.S. market.CEO Jean-Pierre Brulard, who joined the company in May, said the U.S. will be an important drive